$CYTK

Cytokinetics, Incorporated
Stock
63.43
+1.81 · +2.94%
WATCH

Analyst Views on $CYTK

1 Analyst Bullish · 0 Analysts Neutral · 0 Analysts Bear
Bullish 1
Editorial Representation of Brent Kochuba Brent Kochuba BULLISH Moderate
Month 2h

$CYTK is positioned for a high-stakes November 14 FDA catalyst, with unusual upside call-spread activity and muted skew ahead of the decision.

Bearish 0

No Bearish View.

Comments

0 REMARKS